We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Kalendit removes the middleman (agencies) and provides UK nurseries with temporary staff while helping them save up to 50% on staffing fees. Since September, over 150 users joined Kalendit, and it is continuing to add about two workers daily. This company had launched its services in November with four nurseries, and since then, have been successfully processed 49 bookings. With the funds raised, it will hire people and serve thirty nurseries in one year.  By the fifth year, it wants to take 45% of the London market, which equates to 1400 nurseries.
days to go: Expired investment: £82,180
A FCA-authorised and regulated digital credit card on smartphones, for those with modern and busy lifestyles. Jaja aims to offer a fair and transparent banking service that gives consumers greater confidence, control and freedom over their finances. The company has tested their app and card with Visa and has partnered with Asda to offer online credit instantly. Jaja's business model allows revenue to be generated via interest payments from revolving lines of credit. Two products will be offered to consumers; the Jaja Credit Card and Jaja Pay. Both will be suitable for B2B and B2C operations. Investments will be used to launch a beta round for 5,000 users to build a community before the products are publicly released. In addition, Jaja intends to expand its customer service team and produce marketing campaigns for their business.
days to go: Expired investment: £4,957,534
Landbay is a Buy-to Mortgage (BTM) lending platform that provides investors access to a flow of whole-loan high-quality BTL mortgages that can be securitised or held on a balance sheet. Landbay asserts that it does not deploy any of its own balance sheet nor take any credit risk. The company has completed over £600 million of mortgages to date. It argues that it has the mortgage funding, technology and capacity to grow significantly in the £250 billion mortgage market. The company was rated 'Excellent' on consumer review website Trustpilot. It will use 50% of the investment towards technology upgrade, 25% towards marketing and brand development, and 25% towards general marketing expenses.
days to go: Expired investment: £5,129,548
MyT is a cloud-powered subscription-based accounting software designed for small businesses that allows them to submit financial information to Her Majesty's Revenue and Customs (HMRC) under the Making Tax Digital initiative, which is mandatory from April 2023. MyT asserts that its app provides businesses with a simple way to keep track of business finances on the go, send and manage invoices and bills, and record expenses and mileage. The company claims that its app is available on App Store and Google Play and has witnessed 1000+ downloads to date. It claims that it has onboarded over 500 users without any extensive marketing spend. MyT will use half of the investment to implement its marketing plan, a third for developing new technology and the remaining for administrative expenses.

Pitch Rated

73%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £133,543
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button. 
days to go: Expired investment: £1,406,667
Those who work in services, such as the Armed Forces, can find it difficult to access financial products due to their anomalous credit histories compared to non-services personnel. TSFL aims to address this with their advanced risk-modelling platform for underwriters. This will allow tailored insurance, consumer credit and eventually home lending to be sold through TSFL.
days to go: Expired investment: £1,431,885
The SidebySide Partnership is a London based Enterprise Investment Scheme (EIS) Venture Capital (VC) firm. Its purpose is to finance and control the management teams of its investee companies enabling them to become a developed corporate entity. The SidebySide Partnership's focus is on fast-growing technology businesses with £1 - 10 million in revenue. It provides 100% EIS relief on investment with zero initial/ongoing fees charged to investors. The SidebySide Partnership's investment experience of 20+ corporate acquisitions totalling more than $200 million, 20+ private investments, and a rate of interest of 12x over the last 35 years has enabled it to become a dependable platform for upcoming tech businesses. It will use the investment to grow its business across different verticals.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,500,000
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
days to go: Expired investment: £251,600
RiskSave is an online service that makes investment easy and accessible to everyone. As RiskSave do not employ investment advisors their fees are much lower and therefore allowing the client to earn a stronger performance.
days to go: Expired investment: £272,880
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go: Expired investment: £357,179
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph